Logo image of SNDL

SNDL INC (SNDL) Stock Fundamental Analysis

NASDAQ:SNDL - Nasdaq - CA83307B1013 - Common Stock - Currency: USD

1.39  -0.03 (-2.11%)

After market: 1.37 -0.02 (-1.44%)

Fundamental Rating

4

Overall SNDL gets a fundamental rating of 4 out of 10. We evaluated SNDL against 195 industry peers in the Pharmaceuticals industry. While SNDL seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SNDL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SNDL had negative earnings in the past year.
SNDL had a positive operating cash flow in the past year.
In the past 5 years SNDL always reported negative net income.
SNDL had negative operating cash flow in 4 of the past 5 years.
SNDL Yearly Net Income VS EBIT VS OCF VS FCFSNDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of SNDL (-8.15%) is better than 71.79% of its industry peers.
With a decent Return On Equity value of -9.72%, SNDL is doing good in the industry, outperforming 77.44% of the companies in the same industry.
Industry RankSector Rank
ROA -8.15%
ROE -9.72%
ROIC N/A
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
SNDL Yearly ROA, ROE, ROICSNDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

SNDL's Gross Margin of 26.58% is in line compared to the rest of the industry. SNDL outperforms 54.87% of its industry peers.
SNDL's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SNDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
SNDL Yearly Profit, Operating, Gross MarginsSNDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNDL has about the same amount of shares outstanding.
SNDL has more shares outstanding than it did 5 years ago.
SNDL has a better debt/assets ratio than last year.
SNDL Yearly Shares OutstandingSNDL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
SNDL Yearly Total Debt VS Total AssetsSNDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

SNDL has an Altman-Z score of 0.97. This is a bad value and indicates that SNDL is not financially healthy and even has some risk of bankruptcy.
SNDL's Altman-Z score of 0.97 is in line compared to the rest of the industry. SNDL outperforms 58.46% of its industry peers.
The Debt to FCF ratio of SNDL is 3.00, which is a good value as it means it would take SNDL, 3.00 years of fcf income to pay off all of its debts.
SNDL has a better Debt to FCF ratio (3.00) than 90.77% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that SNDL is not too dependend on debt financing.
SNDL has a Debt to Equity ratio of 0.10. This is comparable to the rest of the industry: SNDL outperforms 49.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 3
Altman-Z 0.97
ROIC/WACCN/A
WACC8.57%
SNDL Yearly LT Debt VS Equity VS FCFSNDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 4.62 indicates that SNDL has no problem at all paying its short term obligations.
The Current ratio of SNDL (4.62) is better than 68.21% of its industry peers.
SNDL has a Quick Ratio of 3.12. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
SNDL has a Quick ratio of 3.12. This is comparable to the rest of the industry: SNDL outperforms 59.49% of its industry peers.
Industry RankSector Rank
Current Ratio 4.62
Quick Ratio 3.12
SNDL Yearly Current Assets VS Current LiabilitesSNDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

SNDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.58%, which is quite impressive.
SNDL shows a decrease in Revenue. In the last year, the revenue decreased by -0.07%.
SNDL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.65% yearly.
EPS 1Y (TTM)21.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-485.57%
Revenue 1Y (TTM)-0.07%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%3.62%

3.2 Future

Based on estimates for the next years, SNDL will show a very strong growth in Earnings Per Share. The EPS will grow by 42.75% on average per year.
SNDL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.48% yearly.
EPS Next Y84.85%
EPS Next 2Y20.6%
EPS Next 3Y22.05%
EPS Next 5Y42.75%
Revenue Next Year3.5%
Revenue Next 2Y3.69%
Revenue Next 3Y4.78%
Revenue Next 5Y5.48%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SNDL Yearly Revenue VS EstimatesSNDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
SNDL Yearly EPS VS EstimatesSNDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

SNDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNDL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNDL Price Earnings VS Forward Price EarningsSNDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SNDL is valued cheaper than 81.54% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SNDL is valued cheaply inside the industry as 90.77% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.94
EV/EBITDA 13.78
SNDL Per share dataSNDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

SNDL's earnings are expected to grow with 22.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.6%
EPS Next 3Y22.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SNDL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SNDL INC

NASDAQ:SNDL (7/11/2025, 8:00:02 PM)

After market: 1.37 -0.02 (-1.44%)

1.39

-0.03 (-2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-31 2025-07-31
Inst Owners16.13%
Inst Owner Change0%
Ins Owners0.34%
Ins Owner ChangeN/A
Market Cap357.67M
Analysts82.5
Price Target3.57 (156.83%)
Short Float %1.08%
Short Ratio1.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)177.37%
Min EPS beat(2)9.65%
Max EPS beat(2)345.1%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.28%
Min Revenue beat(2)-6.38%
Max Revenue beat(2)1.83%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)16.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.53
P/FCF 9.94
P/OCF 8.24
P/B 0.44
P/tB 0.53
EV/EBITDA 13.78
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.14
FCFY10.06%
OCF(TTM)0.17
OCFY12.13%
SpS2.63
BVpS3.12
TBVpS2.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.15%
ROE -9.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.58%
FCFM 5.31%
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
F-Score8
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 3
Debt/EBITDA 3.76
Cap/Depr 17.99%
Cap/Sales 1.09%
Interest Coverage N/A
Cash Conversion 194.8%
Profit Quality N/A
Current Ratio 4.62
Quick Ratio 3.12
Altman-Z 0.97
F-Score8
WACC8.57%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)23.85%
Cap/Sales(3y)1.2%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-485.57%
EPS Next Y84.85%
EPS Next 2Y20.6%
EPS Next 3Y22.05%
EPS Next 5Y42.75%
Revenue 1Y (TTM)-0.07%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%3.62%
Revenue Next Year3.5%
Revenue Next 2Y3.69%
Revenue Next 3Y4.78%
Revenue Next 5Y5.48%
EBIT growth 1Y50.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.49%
EBIT Next 3Y150.28%
EBIT Next 5Y93%
FCF growth 1Y220.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y301.43%
OCF growth 3YN/A
OCF growth 5YN/A